| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | 2.16.840.1.113762.1.4.1221.184 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1221.184/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.184 |
| Version | 20240423 |
| Status | active |
| Date | 2024-04-23T01:01:49-04:00 |
| Name | LetrozoleAromataseInhibitor |
| Title | Letrozole (Aromatase inhibitor) |
| Realm | us |
| Authority | hl7 |
| Description | This value set is designed for use in infertility treatment and should not be used for other purposes.
It is important to acknowledge that letrozole is not an FDA-approved medication for infertility, but rather an off-label use with proven effectiveness.
This value set provides a clear distinction between letrozole's use in infertility and its primary use in oncology. |
| Purpose | (Clinical Focus: This value set focuses on letrozole, an aromatase inhibitor medication, specifically in the context of treating infertility. It acknowledges letrozole's primary use in stimulating ovulation in women with ovulation disorders.),(Data Element Scope: This data element captures the administration of letrozole for infertility treatment. It emphasizes letrozole's role in:
Ovulation Induction: Stimulating ovulation in women experiencing infertility due to various causes such as polycystic ovary syndrome (PCOS) or unexplained infertility.),(Inclusion Criteria: Letrozole for the treatment of infertility),(Exclusion Criteria: Any other uses of letrozole beyond infertility treatment (e.g., treatment of estrogen-receptor positive breast cancer)) |
FHIR